Low Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 39 people enrolled
- Started
- 15 Mar 2026
- Expected to end
- 20 May 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Injectable Platelet Rich Fibrin
- Low Level Laser Therapy
- Triamcinolone acetonide (injection)
- Record updated
- 29 September 2026
Who can take part
- Age
- 40 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Clinically and histologically proven painful Bullous/ erosive or atrophic forms of OLP
Who cannot take part
- 1- History of drug induced lichenoid lesions. 2. Presence of systemic conditions as; serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases
- Smoking. 4. Pregnancy or breast-feeding. 5. Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus
- Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites
- Refusing to participate in the study. 8. Vulnerable groups (handicapped)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The Injectable PRF (i-PRF) is a variant of PRF, which is a liquid blood derivative rich in leukocytes and acts as a growth factor release, with its potential anti-inflammatory role, it may alleviate the symptoms of OLP.
Read full original descriptionShow less
Low Level Laser Therapy (LLLT) emits short wavelength red or infrared light between (500-1100 nm) with a low water absorption. This light can reach a depth of 3 mm to 15 mm in both soft and hard tissues, the biostimulatory effect of laser irradiation results in physiological, metabolic, and functional changes in living microorganisms. The investigators compared the clinical effectiveness of LLLT combined with (i-PRF) to the application of (i-PRF) alone and to that of topical corticosteroid regimen in symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on expression of Tumor necrosis factor alpha (TNF-alpha) and Vascular endothelial growth factor (VEGF) in salivary samples from OLP patients.
The 3 groups in the trial
- Injectable Platelet Rich Fibrin (i-PRF)Treatment being tested
1 ml of (i-PRF) obtained after centrifuging 10 ml of peripheral venous blood from OLP patient, will be injected once weekly for 1 month.
Treatment: Injectable Platelet Rich Fibrin
- Low Level Laser therapy (LLLT) / (i -PRF)Treatment being tested
1 ml of (i- PRF) once weekly for 1 month followed by (LLLT) at 940 nm for 180 seconds twice weekly, 8 sessions for 1 month.
Treatment: Injectable Platelet Rich Fibrin and Low Level Laser Therapy
- Topical corticosteroidExisting treatment, for comparison
Injectional triamcinolone acetonide (TA) (40 mg/ml; Epico) once weekly for 1 month
Treatment: Triamcinolone acetonide (injection)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low Level Laser Therapy Combined With Injectable Platelet Rich Fibrin Versus Injectable Platelet Rich Fibrin in Management of Symptomatic Oral Lichen Planus : A Randomized Controlled Clinical Study With Biochemical Analysis
- Record updated
- 29 September 2026